MXPA05006981A - Derivados de prostaglandinas para el tratamiento de la molestia abdominal. - Google Patents

Derivados de prostaglandinas para el tratamiento de la molestia abdominal.

Info

Publication number
MXPA05006981A
MXPA05006981A MXPA05006981A MXPA05006981A MXPA05006981A MX PA05006981 A MXPA05006981 A MX PA05006981A MX PA05006981 A MXPA05006981 A MX PA05006981A MX PA05006981 A MXPA05006981 A MX PA05006981A MX PA05006981 A MXPA05006981 A MX PA05006981A
Authority
MX
Mexico
Prior art keywords
prostaglandins
derivatives
abdominal discomfort
treating abdominal
chloride channel
Prior art date
Application number
MXPA05006981A
Other languages
English (en)
Spanish (es)
Inventor
Sachiko Kuno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32717850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05006981(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of MXPA05006981A publication Critical patent/MXPA05006981A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/56—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MXPA05006981A 2002-12-27 2003-12-26 Derivados de prostaglandinas para el tratamiento de la molestia abdominal. MXPA05006981A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43646202P 2002-12-27 2002-12-27
US43646302P 2002-12-27 2002-12-27
PCT/JP2003/016857 WO2004060377A1 (en) 2002-12-27 2003-12-26 Derivatives of prostaglandins for treating abdominal discomfort

Publications (1)

Publication Number Publication Date
MXPA05006981A true MXPA05006981A (es) 2005-12-14

Family

ID=32717850

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006981A MXPA05006981A (es) 2002-12-27 2003-12-26 Derivados de prostaglandinas para el tratamiento de la molestia abdominal.

Country Status (15)

Country Link
US (3) US7795312B2 (enExample)
EP (2) EP2281564A3 (enExample)
JP (2) JP4889219B2 (enExample)
KR (2) KR20120045051A (enExample)
CN (1) CN1753680B (enExample)
AR (1) AR042670A1 (enExample)
AU (1) AU2003292556B2 (enExample)
BR (1) BRPI0317740B8 (enExample)
CA (1) CA2510051C (enExample)
ES (1) ES2591252T3 (enExample)
MX (1) MXPA05006981A (enExample)
NO (1) NO335441B1 (enExample)
NZ (1) NZ541110A (enExample)
TW (1) TWI336254B (enExample)
WO (1) WO2004060377A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
EP1562604B1 (en) * 2002-10-23 2012-01-04 Sucampo AG Prostaglandin compounds for the treatment of obesity
US8337891B2 (en) * 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI387454B (zh) 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
EP1871380B1 (en) * 2005-04-12 2011-10-19 Sucampo AG Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
US7868045B2 (en) 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
JP2010519177A (ja) * 2007-02-27 2010-06-03 スキャンポ・アーゲー ミトコンドリアを保護するための組成物および方法
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
JP5797655B2 (ja) * 2009-09-18 2015-10-21 アドラー・コーポレーション 消化管障害のためのオピオイド受容体アンタゴニストの使用
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013161973A1 (en) * 2012-04-23 2013-10-31 Sucampo Ag Method for treating irritable bowel syndrome with diarrhea
CN105102432B (zh) 2012-10-15 2019-01-04 Epizyme股份有限公司 经取代的苯化合物
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1581886A (en) * 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
TW224942B (enExample) 1990-04-04 1994-06-11 Adka Ueno Kk
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US6242485B1 (en) 1996-06-10 2001-06-05 R-Tech Ueno Endothelin antagonist
US6046239A (en) * 1997-08-05 2000-04-04 American Home Products Corporation Anthranilic acid analogs
EP0978284B1 (en) * 1997-11-28 2008-07-23 Sucampo AG Use of 15-keto-prostaglandin-e compounds as endothelin antagonists
US6492417B1 (en) * 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
DE60039727D1 (de) * 1999-10-15 2008-09-11 Sucampo Ag Neue Zusammensetzung enthaltend eine bicyclische Verbindung und ein Glycerid
JP4183943B2 (ja) * 2000-04-06 2008-11-19 スキャンポ・アーゲー １５−ケトプロスタグランジンを含む胆汁分泌促進剤組成物
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
AR035242A1 (es) * 2001-05-18 2004-05-05 Sucampo Ag Uso de un lipido bioactivo halogenadopara preparar una composicion catartica y compuesto lipido bioactivo halogenado
AU2002330747B2 (en) 2001-08-31 2007-07-19 Sucampo Ag Prostaglandin analogs as chloride channel opener
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel

Also Published As

Publication number Publication date
ES2591252T3 (es) 2016-11-25
BRPI0317740B8 (pt) 2021-05-25
EP2281564A2 (en) 2011-02-09
WO2004060377A1 (en) 2004-07-22
NO335441B1 (no) 2014-12-15
BR0317740A (pt) 2005-11-22
EP2281564A3 (en) 2012-09-05
EP1575596B1 (en) 2016-06-22
CN1753680A (zh) 2006-03-29
US20100298424A1 (en) 2010-11-25
KR20120045051A (ko) 2012-05-08
US20130217770A1 (en) 2013-08-22
CA2510051C (en) 2016-07-05
JP4889219B2 (ja) 2012-03-07
US20040138308A1 (en) 2004-07-15
JP2012031202A (ja) 2012-02-16
TW200418491A (en) 2004-10-01
AR042670A1 (es) 2005-06-29
KR101164838B1 (ko) 2012-07-11
EP1575596A1 (en) 2005-09-21
CN1753680B (zh) 2010-12-08
AU2003292556B2 (en) 2009-09-10
BRPI0317740B1 (pt) 2018-09-18
NO20053623D0 (no) 2005-07-26
TWI336254B (en) 2011-01-21
JP2006513232A (ja) 2006-04-20
NZ541110A (en) 2008-11-28
NO20053623L (no) 2005-09-26
CA2510051A1 (en) 2004-07-22
AU2003292556A1 (en) 2004-07-29
US7795312B2 (en) 2010-09-14
KR20050086950A (ko) 2005-08-30

Similar Documents

Publication Publication Date Title
EP2281564A3 (en) Derivatives of prostaglandins for treating abdominal discomfort
DE60329001D1 (en) 8-hydroxychinolinderivate
TNSN04065A1 (en) Treatment of acute myeloid leukemia with indolinone compounds
SI1485360T1 (sl) Blokatorji natrijevih kanalov
GB0318438D0 (en) Early entry
FR12C0052I1 (enExample)
WO2003070163A3 (en) Prostacyclin derivatives for treating cancer
GB0318343D0 (en) No title
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
MXPA04005886A (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6.
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
GEP20084499B (en) USE OF INTERFERON-ß FOR TREATMENT OF RENAL FAILURE
SI1694318T1 (sl) (S)-2-N-propilamino-5-hidroksitetralin kot terapevtsko sredstvo z agonističnim učinkom na D3
MXPA04003087A (es) Derivados de cromano como ligados de 5-hidroxitriptamina-6.
MXPA04007391A (es) Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
MY138263A (en) Therapeutic chroman compounds
UA88773C2 (ru) Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря
IL173377A0 (en) Compounds for the treatment of metabolic disorders
SG139747A1 (en) Inhibitors of the mutant form of kit
SE0101082D0 (sv) Novel use
SI1532131T1 (sl) Motilidne spojine
SG165159A1 (en) Process for preparing 6-alkylidene penem derivatives
GB0129457D0 (en) Method of treatment
PL377176A1 (pl) N-Sulfonylo-4-metylenoamino-3-hydroksy-2-pirydony
MXPA04003544A (es) Benzotriazepinas como ligandos del receptor de gastrina y colecistocinina.

Legal Events

Date Code Title Description
FG Grant or registration
HH Correction or change in general